|
|
- NHS Foundation Trusts (England) - Medical Director
- NHS Foundation Trusts (England) - Chief Executive
- NHS Trusts (England) - Medical Director
- NHS Trusts (England) - Chief Executive
|
|
|
- MHRA (Medicines) Drug Alerts (Various Recipients)
- Other contacts
- Independent Healthcare Providers (registered with CAS)
- Clinical Commissioning Groups
- NHS Regional Offices
- Special Health Authorities
- CMO Urgent Messages - Non-NHS Recipients on Public Health Link
- MHRA (Medicines) Drug Alerts - Non-NHS Recipients
- Territorial CMOs in Northern Ireland, Scotland & Wales
- Regional Directors of Public Health
- Consultants in Communicable Diseases
- CMO Urgent Messages - Recipients on Public Health Link
- Director of Public Health
- DHSC Supply Disruption - Medicines
|
| Title: |
|
Updated Publication of Remdesivir guidance for patients hospitalised with Covid-19 (adults and children aged 12 years and older)
|
| Broadcast content: |
|
NHS trusts/health boards are advised to consider prescribing a course of
remdesivir to eligible hospitalised patients with COVID-19 pneumonia, typically
with dexamethasone as standard of care. This now includes re-admitted patients,
patients with end-stage renal disease on haemodialysis and significantly
immunocompromised patients, in line with the criteria in the updated NHS
Interim Clinical Commissioning Policy.
|
| Additional information: |
|
This alert does not need to be cascaded to Primary Care
|